Martha Stewart's Controversial GLP-1 Commercial Might Actually Be 'A Good Thing,' According To Experts

Filed 1h ago · Via HuffPost · The Buffoon Desk

THIS STORY IS SCORED

Merry Go Slower

Kevin MacLeod · incompetech.com · CC BY 4.0

Photo: Meissen Manufactory · CC0 · via Wikimedia Commons

Foundayo, an FDA-approved oral GLP-1 pill from Eli Lilly, features Martha Stewart in a new Instagram ad that openly states 'Martha does not take Foundayo' onscreen, while a second, actor-portrayal-labeled woman describes results on the drug. The disclosure sparked backlash from viewers questioning why a non-user should be trusted to sell a medication.

A regulatory attorney told HuffPost the ad fully complies with FDA rules since it properly discloses Stewart's non-use and includes required side-effect notices; the agency, he noted, cares about disclosure, not endorsement authenticity. Marketing consultants suggested Stewart's appeal lies in lending the drug a lifestyle association with her core demographic, women 50 to 64, who are also GLP-1's most common users.

Stewart's team told HuffPost the partnership is 'grounded in education, empowerment' and helping people make informed decisions; Lilly did not respond to a request for comment.

The full dispatch is available from the source below.

✒ FROM THE EDITORIAL DESK

There's something almost admirable about an ad that tells you upfront the spokesperson doesn't use the product, like a used boat dealer mentioning the engine's never been in water. It's honest in the narrowest legal sense and dishonest in every sense that matters to a person deciding whether to trust a familiar face. Compliant is not the same as convincing, and the FDA apparently isn't in the business of telling the difference.

Source: Read the original at HuffPost → Scored: Merry Go Slower · Kevin MacLeod · CC BY 4.0

Read it scored.

Every story, every clown, every kazoo — in your pocket. Music plays automatically. Regret is optional.

GET IT ON iOS GET IT ON ANDROID

OR FOLLOW THE DESK ON BLUESKY →